UNITED STATES DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE

ANNUAL REPORT OF RESEARCH FACILITY
(TYPE OR PRINT)

1. CERTIFICATE NUMBER: 57-F-0004
CUSTOMER NUMBER: 947

FORM APPROVED
OMB NO. 0579-0036

Centers for Disease Control and Prevention
1600 Clifton Road N.E.
Mailstop C-17
Atlanta, GA 30333

Telephone: (404) 639-2462

NOV 26 2002

2. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, or experimentation, or held for these purposes. Attach additional sheets if necessary.)

FACILITY LOCATIONS (Sites) - See Attached Listing

REPORT OF ANIMALS USED BY OR UNDER CONTROL OF RESEARCH FACILITY (Attach additional sheets if necessary or use APHIS Form 7023A.)

A. Animals Covered By The Animal Welfare Regulations	B. Number of animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery but not yet	C. Number of animals upon which teaching, research, experiments, or tests were conducted involving no pain, distress, or use of pain-relieving drugs.	D. Number of animals upon which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, a	E. Number of animals upon which teaching, experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or tranquilizing drugs would have adversely affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used must be attached to	F. TOTAL NUMBER OF ANIMALS (COLUMNS C + D + E)
1. Dogs	Out of Scope				
2. Cats					
3. Guinea Pigs					
4. Hamsters					
5. Rabbits					
6. Non-human Primates	104	60	995	63	1118
7. Sheep	Out of Scope				
8. Pigs					
9. Other Farm Animals					
10. Other Animals					
11. Total					

INSURANCE STATEMENTS

1) Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, and following actual research, teaching, testing, surgery, or experimentation were followed by this research facility.

2) Each principal investigator has considered alternatives to painful procedures.

3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all such exceptions is attached to this annual report. In addition to identifying the IACUC-approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected.

4) The attending veterinarian for the research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and

CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL
(Chief Executive Officer or Legally Responsible Institutional Official)

SIGNATURE OF C.E.O. OR INSTITUTIONAL OFFICIAL	NAME & TITLE OF C.E.O. OR INSTITUTIONAL OFFICIAL (Type or Print)	DATE SIGNED
Dixie E. Snider Jr. M.D.	Dixie E. Snider Jr., M.D., M.P.H. Assistant Surgeon General Associate Director for Science	EC 12/2/02

APHIS FORM 7023 (AUG 91) (Replaces VS FORM 18-23 (OCT 88) which is obsolete.)

Thursday, November 21, 2002

Centers for Disease Control and Prevention
Atlanta, Georgia

Registration Number: 57-F-0004

Out of Scope

1185COLMONB – 24 Non-human primates, Pain Class III –
Agent: *Plasmodium falciparum* FVO and Malayan Camp strains
Objective: Immunization trial (using two forms of rMS-1p42 and three adjuvants) testing for 1) efficacy and immunogenicity, 2) induction of protective immunity, 3) parallel vaccinations, and 4) comparability of data between immunization trials in *Aotus nancymai* and clinical trial immunization in humans using the same adjuvants, schedules, and clinical grade cGMP antigens.
Explanation of Class III Pain: Use of Complete Freund's Adjuvant

1186BARMONB – 6 Non-human primates, Pain Class III –
Agent: *Plasmodium falciparum* Vietnam Oak Knoll, Uganda pal Alto & Indochine I strains
Objective: Validate *S. B. boliviensis* as an immunizations trial model equal to *A. nancymai*. Evaluate the immunogenicity and efficacy of milk derived rMSP-1p42 in comparison to the known efficacy of this rMSP-1p42 in *Aotus nancymai* when adjuvanted with RCA in protecting against high density parasitemia from the FVO strain of P. falciparum.
Explanation of Class III Pain: Use of Freund's Adjuvant

1204RUPMONL – 32 Non-human primates, Pain Class III –
Agent: Rabies Virus
Objective: Evaluate the Immunogenicity, safety, and efficacy of different rabies vaccines, and purified, heat-treated ERIG, and varius Mabs (murine, chimeric, human, and recombinant) in conjunction with rabies vaccine, as a potential replacement for HRIG, in squirrel monkeys during vaccination against several variants of lethal street rabies virus.
Explanation of Class III Pain: It is assumed that nearly all the control animals and possibly a few of the vaccinates will succumb to rabies. Animals will be euthanized when two compatible signs of rabies are observed.

1250WILMONC – 1 Non-human primate, Pain Class III –
Agent: *Baylisascaris procyonis*
Objective: To generate large quantities of diagnostic assay reagents (sera and infected tissues) to study the pathological effects of infection, and describe the pattern of disease.
Explanation of Class III Pain: *Baylisascaris procyonis* cause visceral larva migrans and cerebrospinal parasitosis in infected humans. The severity and progression of CNS disease depends on the number of *B. procyonis* larvae entering the brain. An estimated 5-7% of larvae will invade the brain. In humans, recognized *B. procyonis* infection has typically caused fatal disease or severe sequellae. Signs of CNS disease may appear as early as 2-4 weeks post infection. Typical signs in human infections include sudden lethargy, loss of muscle coordination, decreased head control, torticollis, ataxia, and nystagmus, progressing to stupor, extensor rigidity or hypotonia, coma and death.

Out of Scope

Thursday, November 21, 2002

Centers for Disease Control and Prevention
Atlanta, Georgia

Registration Number: 57-F-0004

Facility Locations (Sites)

1. (b)(2) Morgantown, WV (b)(2)
2. (b)(2) Ft. Collins, CO (b)(2)
3. (b)(2) (b)(2) Atlanta, GA (b)(2)
4. (b)(2) (b)(2) Chamblee, GA (b)(2)
5. (b)(2) (b)(2) Lawrenceville, GA (b)(2)